These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35936102)

  • 1. Discovery of BRAF/HDAC Dual Inhibitors Suppressing Proliferation of Human Colorectal Cancer Cells.
    Li Y; Huang Y; Cheng H; Xu F; Qi R; Dai B; Yang Y; Tu Z; Peng L; Zhang Z
    Front Chem; 2022; 10():910353. PubMed ID: 35936102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
    Yang Z; Shen M; Tang M; Zhang W; Cui X; Zhang Z; Pei H; Li Y; Hu M; Bai P; Chen L
    Eur J Med Chem; 2019 Sep; 178():116-130. PubMed ID: 31177073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and Biological Evaluation of 2-Anilino-4-Triazolpyrimidine Derivatives as CDK4/HDACs Inhibitors.
    Wang S; Han S; Cheng W; Miao R; Li S; Tian X; Kan Q
    Drug Des Devel Ther; 2022; 16():1083-1097. PubMed ID: 35431540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
    Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring
    Fu H; Cheng L; Jin Y; Cheng L; Liu M; Chen L
    Mol Ther Oncolytics; 2019 Mar; 12():235-245. PubMed ID: 30847387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2.
    Yu Y; Ran D; Jiang J; Pan T; Dan Y; Tang Q; Li W; Zhang L; Gan L; Gan Z
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2136-2140. PubMed ID: 31272794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis and Biological Evaluation of Novel Benzoylimidazole Derivatives as Raf and Histone Deacetylases Dual Inhibitors.
    Chen X; Gong G; Chen X; Song R; Duan M; Qiao R; Jiao Y; Qi J; Chen Y; Zhu Y
    Chem Pharm Bull (Tokyo); 2019; 67(10):1116-1122. PubMed ID: 31582631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
    Liang X; Zang J; Li X; Tang S; Huang M; Geng M; Chou CJ; Li C; Cao Y; Xu W; Liu H; Zhang Y
    J Med Chem; 2019 Apr; 62(8):3898-3923. PubMed ID: 30901208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
    Wang H; Quan H; Lou L
    Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy.
    Zhang M; Wei W; Peng C; Ma X; He X; Zhang H; Zhou M
    Bioorg Med Chem Lett; 2021 Oct; 49():128286. PubMed ID: 34314844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of quinazoline derivatives as dual HDAC1 and HDAC6 inhibitors for the treatment of cancer.
    Chen J; Sang Z; Jiang Y; Yang C; He L
    Chem Biol Drug Des; 2019 Mar; 93(3):232-241. PubMed ID: 30251407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
    Pojani E; Barlocco D
    Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis, and Structure-Activity relationships of Evodiamine-Based topoisomerase (Top)/Histone deacetylase (HDAC) dual inhibitors.
    Zhu F; Meng X; Liang H; Sheng C; Dong G; Liu D; Wu S
    Bioorg Chem; 2022 May; 122():105702. PubMed ID: 35286923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
    Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
    Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
    Tang Z; Yuan X; Du R; Cheung SH; Zhang G; Wei J; Zhao Y; Feng Y; Peng H; Zhang Y; Du Y; Hu X; Gong W; Liu Y; Gao Y; Liu Y; Hao R; Li S; Wang S; Ji J; Zhang L; Li S; Sutton D; Wei M; Zhou C; Wang L; Luo L
    Mol Cancer Ther; 2015 Oct; 14(10):2187-97. PubMed ID: 26208524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity.
    Zhao Q; Xiong SS; Chen C; Zhu HP; Xie X; Peng C; He G; Han B
    Front Oncol; 2022; 12():972372. PubMed ID: 35992773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harmine-based dual inhibitors targeting histone deacetylase (HDAC) and DNA as a promising strategy for cancer therapy.
    Lu D; Qu L; Wang C; Luo H; Li S; Yin F; Liu X; Chen X; Luo Z; Cui N; Peng W; Ji L; Kong L; Wang X
    Bioorg Chem; 2022 Mar; 120():105604. PubMed ID: 35051708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 2-(aminopyrimidin-5-yl)-4-(morpholin-4-yl)-6- substituted triazine as PI3K and BRAF dual inhibitor.
    Wang HY; Shen Y; Zhang H; Hei YY; Zhao HY; Xin M; Lu SM; Zhang SQ
    Future Med Chem; 2018 Oct; 10(20):2445-2455. PubMed ID: 30325235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
    Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
    Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.